



AMENDMENTS TO THE CLAIMS:


This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-10 (Cancelled).

11. (Currently Amended) A pharmaceutical composition comprising at least one compound of formula (C) or (D) and a pharmaceutically acceptable carrier which is useful in a medicine




wherein -X' is



m is 0 or 1;

Y' is



Q is CH or N;

K is S or O;

v is 0, 1, or 2;

R^6 is CO_2H , CO_2Alkyl , CO_2Aryl , CO_2NH_2 , $CO_2Aralkyl$, SO_3H , SO_2NH_2 , $PO(OH)_2$, 1-H-tetrazolyl, CHO, $COCH_3$, CH_2OH , NH_2 , NHalkyl, $N(Alkyl)Alkyl'$, OCH_3 , CH_2OCH_3 , SH, F, Cl, Br, I, CH_3 , CH_2CH_3 , CN, or CF_3 ;

R^7 , independently from R^6 , is H, CH_3 , CH_2CH_3 , CF_3 , F, Cl, Br, I, CN, or NO_2 ;

R^8 , independently from R^6 and R^7 , is H, CH_3 , CH_2CH_3 , CF_3 , F, Cl, Br, I, CN, NO_2 , or R^6 ;

R^{9a} is H, NO_2 , CF_3 , F, Cl, Br, I, CN, CH_3 , OCH_3 , SH, or NH_2 ;

R^{9b} , independently from R^{9a} , is H, NO_2 , CF_3 , F, Cl, Br, I, CN, CH_3 , OCH_3 , SH, or NH_2 ;

R^{10} is CO_2H , CO_2alkyl , CO_2aryl , CO_2NH_2 , $CO_2aralkyl$, CH_2SO_3H , $CH_2SO_2NH_2$, $CH_2PO(OH)_2$, 1-H-tetrazolyl, CHO, $COCH_3$, CH_2OH , CH_2NH_2 , $CH_2NHalkyl$, $CH_2N(alkyl)alkyl'$, CH_2OCH_3 , or CH_2SH ;

R^{11} is CO_2H , CO_2alkyl , CO_2aryl , CO_2NH_2 , $CO_2aralkyl$, SO_3H , SO_2NH_2 , $PO(OH)_2$, 1-H-tetrazolyl, CHO, $COCH_3$, OH, NH_2 , NHalkyl, $N(alkyl)alkyl'$, OCH_3 , or SH;

s is 1;

t is 0, 1, or 2;

-W- is $-(CH_2-)$, cis- $CH=CH-$ or trans- $CH=CH-$, and v is 0, 1, or 2;

in case that R^6 is NH_2 , R^7 or R^8 or R^{9a} must not be H; and

in case that -W- is cis- $CH=CH-$ or trans- $CH=CH-$, R^6 must not be NH_2 or SH;

or the pharmaceutically acceptable salts, esters, or amides of the compounds of formula (C) or (D).

12. (Previously Presented) A pharmaceutical composition of claim 11 wherein the at least one compound is a compound of formula (C).

13. (Previously Presented) A pharmaceutical composition of claim 11 wherein the at least one compound is a compound of formula (D).

14. (Currently Amended) Use of compounds having the structure of formula (C) or (D) as defined in claim 1 for the preparation of a medicine for the treatment of a patient, A method of inhibiting the binding of P-selectin, L-selectin or E-selectin to sLe^x or sLe^a and tyrosinesulfate residues in a patient comprising the administration of a compound having the structure of formula (C) or (D) as defined in claim 11.

15. (Currently Amended) Use of compounds having the structure of formula (C) or (D) as defined in claim 1 for the preparation of a medicine for the A method of treating, diagnosing, or preventing treatment, diagnosis, or prophylaxis of inflammatory disorders in a patient comprising the administration of a compound having the structure of formula (C) or (D) as defined in claim 11.

16. (Currently Amended) Use of compounds having the structure of formula (C) or (D) as defined in claim 1 for the preparation of a medicine for the treatment of A method of treating Chronic Obstructive Pulmonary Disease (COPD), acute respiratory distress syndrome (ARDS), Crohn's disease, septic shock, sepsis,

chronic inflammatory diseases, psoriasis, atopic dermatitis, rheumatoid arthritis, reperfusion injury that occurs following heart attacks, strokes, atherosclerosis, organ transplants, traumatic shock, multi-organ failure, or an autoimmune disease selected from multiple sclerosis, asthma, and inflammatory bowel disease in a patient comprising the administration of a compound having the structure of formula (C) or (D) as defined in claim 11.